'Serial Killer’ CAR-T Could Help Autolus Bounce Back
After A Hard Year, The UK Biotech Looks For ASH Data Upturn
Data presentations at next week’s ASH meeting will be vital for Autolus to restore confidence in pipeline.
You may also be interested in...
Blueprint and Zymeworks raise $300m-plus in follow-on offerings. Also, Arcutis, Black Diamond and Annovis bring the 2020 US IPO count to four; Spring Bank, Surface Oncology and Decibel reveal strategic shifts; and Harmony’s $200m in venture debt leads recent VC deals.
Astellas pays to play in next-generation immuno-oncology through deal for young, privately held US venture and its novel modulation platform.
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.